Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2008Virchows ArchivOpen Access

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program

View Full Paper
Ask AI
Bookmark
Share

Authors

JKJ. Han van KriekenUniversity of Southern CaliforniaAJAndreas JungAmgen (United States)TKThomas KirchnerFH Aachen

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Krieken et al. (2008) studied this question.

synapsesocial.com/papers/6a710a015671bbf00bc2d223https://doi.org/10.1007/s00428-008-0665-y
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Detection of K‐ras exon 1 mutations by constant denaturant capillary electrophoresis2004 · 12 citations
  2. 2Epidermal growth factor receptor expression in colorectal cancer1990 · 80 citations
  3. 3Kisten ras mutations in patients with colorectal cancer: the “RASCAL II” study.2001 · 891 citations
  4. 4No Duplicate KRAS Mutation is Identified on the Same Allele in Gastric or Colorectal Cancer Cells with Multiple KRAS Mutations2007 · 28 citations
  5. 5Detection of stool DNA mutations before and after treatment of colorectal neoplasia2005 · 49 citations